daphni reaches final close for Daphni Blue at €260 million
Paris-based venture capital firm daphni has reached the final closing of its latest vehicle, Daphni Blue, at €260 million, exceeding its initial target and completing the raise in under nine months from first close. The firm said the fund is designed to convert Europe’s scientific output into globally relevant startups aimed at addressing major environmental and societal challenges.
The firm has already begun deploying capital, backing nine early-stage, science-based companies. Among the first investments are OWLO, EverDye, and Karavela, with two additional TechBio deals in the pipeline—one expected in France and another in the UK.
A bet on defensible innovation as software and AI commoditize
Pierre-Eric Leibovici, co-founder and managing partner at daphni, framed the fund’s thesis as a response to a shifting innovation landscape in which software advantages can erode quickly and artificial intelligence accelerates replication. “In a world where technology is increasingly commoditized and AI is redefining how innovation is built, we’re convinced the strongest long-term value comes from deep scientific breakthroughs,” he said in a public statement.
That approach places emphasis on scientific intellectual property and research-driven differentiation—assets the firm believes are harder to copy than product features or distribution tactics. “To create sustainable value you need an additional element, which is intellectual property that comes from science,” Leibovici added, warning of “a brutal return to reality” for companies that raised capital without building durable value or market share.
Fund strategy: early-stage science, with room to follow on
Daphni Blue will focus on early-stage investments in “scientist-entrepreneurs” whose companies are rooted in core research spanning biology, chemistry, physics, mathematics, and life sciences. The fund’s initial cheque sizes range from €500,000 to €10 million, with the capacity for follow-on investments up to €20 million. Over its lifecycle, the firm expects to support roughly 40 to 50 companies.
The strategy builds on daphni’s track record as an early investor in French tech successes including unicorns Back Market and Swile, but it also signals an increased emphasis on research-intensive ventures rather than predominantly software-led models.
Early portfolio highlights
The first wave of investments under the Daphni Blue banner illustrates the fund’s “lab-to-market” ambition:
- OWLO, spun out of Institut Langevin, is developing real-time, non-invasive, label-free 3D microscopy aimed at fertility and pharmaceutical research.
- EverDye is commercializing an eco-conscious dyeing process based on patented green chemistry, designed to reduce environmental impact without requiring new industrial machinery.
- Karavela, a spinoff from INRIA, is building a brain foundation model using functional MRI data to enable new digital biomarkers and potential brain–machine interface applications.
- Neotis is pursuing immunotherapies targeting senescent cells, with the goal of treating age-related chronic diseases.
Europe’s research base becomes an investable pipeline
While science-based venture investing remains a smaller segment of the broader VC market, daphni argues that Europe has structural advantages that are increasingly investable—particularly its public research infrastructure and large talent pool. The firm points to the continent’s estimated 2.2 million researchers as a deep reservoir for future startups, especially when paired with mechanisms that make commercialization easier.
To that end, daphni said it is working with leading French research institutions including INRIA, INSERM, Institut Langevin, and Institut Curie, while also tapping broader European ecosystems. The firm’s model combines digital infrastructure with an active community of investors and founders, aiming to shorten the path from scientific discovery to product development and market entry.
Part of a broader European push into DeepTech and climate
Daphni Blue’s final close arrives amid sustained fundraising for European DeepTech, science-based, and climate-oriented strategies. In early 2026, Copenhagen-based Footprint Fund I announced a €76 million fund targeting around 30 early-stage climate and DeepTech startups across Northern Europe. Berlin-based b2venture also reached a €150 million hard cap for its fifth fund.
At the end of 2025, U2V—a spin-off from Earlybird-X—launched a €60 million vehicle focused on pre-seed and seed DeepTech companies emerging from European technical universities, reinforcing the same lab-to-market narrative. In Southern Europe, Lisbon-based Armilar Venture Partners raised €120 million for its fourth fund, targeting DeepTech and digital transformation startups across Spain, Portugal, and the wider region.
Together with Daphni Blue, these announcements total roughly €666 million in disclosed capital flowing into adjacent science-driven strategies over 2025–2026, underscoring continued institutional appetite for long-horizon, research-intensive innovation.
Linking returns to accountability
daphni said Daphni Blue will incorporate an impact component by tying part of its carried interest to ESG performance—an approach intended to align financial outcomes with measurable responsibility. The structure reflects a broader trend among limited partners seeking both breakthrough innovation and clearer accountability around environmental and social outcomes.
With €260 million in commitments and early deployments already underway, daphni is positioning Daphni Blue as a scaled bridge between European research labs and venture-backed company building—betting that the next generation of category-defining startups will be built on scientific breakthroughs that are difficult to commoditize.
Related
